AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups

AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.